How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?

Most patients with PGNMID have no detectable disease in their marrow or blood and urine protein cannot adequately be monitored.

Answer from: Medical Oncologist at Community Practice

Monoclonal gammopathy of renal significance includes a variety of renal pathologies: 1) MIDD (LCDD, LHCDD, HCDD); 2) Monoclonal immunotactoid glomerulonephritis or type 1 cryoglobulinemic glomerulonephritis; 3) Light chain proximal tubulopathy or crystal-storing histiocytosis; 4) C3 glomerulopathy w...

Comments

Medical Oncologist at University of Chicago
This is a great explanation. That’s the tric...

Medical Oncologist at Texas Oncology Dallas
I had a patient with PGNMID associated with mantle...

Please select the option that best describes you:

How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?

Related Questions